Senolytics rejuvenate aging cardiomyopathy in human cardiac organoids.

Mariangela Scalise, Eleonora Cianflone, Claudia Quercia, Loredana Pagano, Antonio Chiefalo, Antonio Stincelli, Annalaura Torella, Barbara Puccio, Gianluca Santamaria, Hiram P Guzzi, Pierangelo Veltri, Antonella De Angelis, Konrad Urbanek, Georgina M Ellison-Hughes, Daniele Torella, Fabiola Marino

Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro 88100, Italy; Centre for Human and Applied Physiological, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK. · pubmed

Paper

Abstract

Human cardiac organoids closely replicate the architecture and function of the human heart, offering a potential accurate platform for studying cellular and molecular features of aging cardiomyopathy. Senolytics have shown potential in addressing age-related pathologies but their potential to reverse aging-related human cardiomyopathy remains largely unexplored.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper investigates the use of senolytics to rejuvenate aging cardiomyopathy, which is directly related to the aging process and seeks to address a root cause of age-related cardiac dysfunction. While the research is solid and contributes to the understanding of senolytics in the context of aging, the findings may not be groundbreaking enough to significantly advance the field, hence the moderate impact score.

Author of this paper? Send a correction.